CDNA
Price
$12.07
Change
-$1.03 (-7.86%)
Updated
Aug 7 closing price
Capitalization
548.33M
83 days until earnings call
HBIO
Price
$0.51
Change
+$0.03 (+6.25%)
Updated
Aug 7 closing price
Capitalization
184.01M
3 days until earnings call
Interact to see
Advertisement

CDNA vs HBIO

Header iconCDNA vs HBIO Comparison
Open Charts CDNA vs HBIOBanner chart's image
CareDx
Price$12.07
Change-$1.03 (-7.86%)
Volume$2.71M
Capitalization548.33M
Harvard Bioscience
Price$0.51
Change+$0.03 (+6.25%)
Volume$302.27K
Capitalization184.01M
CDNA vs HBIO Comparison Chart in %
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. HBIO commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Hold and HBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CDNA: $12.07 vs. HBIO: $0.51)
Brand notoriety: CDNA and HBIO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 171% vs. HBIO: 19%
Market capitalization -- CDNA: $548.33M vs. HBIO: $184.01M
CDNA [@Medical Specialties] is valued at $548.33M. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.69B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, HBIO is a better buy in the long-term than CDNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 6 TA indicator(s) are bullish while HBIO’s TA Score has 4 bullish TA indicator(s).

  • CDNA’s TA Score: 6 bullish, 4 bearish.
  • HBIO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CDNA is a better buy in the short-term than HBIO.

Price Growth

CDNA (@Medical Specialties) experienced а -1.75% price change this week, while HBIO (@Medical Specialties) price change was +10.39% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.63%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -3.41%.

Reported Earning Dates

CDNA is expected to report earnings on Oct 30, 2025.

HBIO is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Medical Specialties (+0.63% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($548M) has a higher market cap than HBIO($184M). CDNA YTD gains are higher at: -43.624 vs. HBIO (-75.635). HBIO has higher annual earnings (EBITDA): 8.03M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. HBIO (4.28M). CDNA has less debt than HBIO: CDNA (34.2M) vs HBIO (42.8M). CDNA has higher revenues than HBIO: CDNA (280M) vs HBIO (112M).
CDNAHBIOCDNA / HBIO
Capitalization548M184M298%
EBITDA-84.92M8.03M-1,057%
Gain YTD-43.624-75.63558%
P/E RatioN/AN/A-
Revenue280M112M250%
Total Cash235M4.28M5,487%
Total Debt34.2M42.8M80%
FUNDAMENTALS RATINGS
CDNA vs HBIO: Fundamental Ratings
CDNA
HBIO
OUTLOOK RATING
1..100
6174
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4699
PRICE GROWTH RATING
1..100
9256
P/E GROWTH RATING
1..100
922
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDNA's Valuation (95) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that CDNA’s stock grew similarly to HBIO’s over the last 12 months.

CDNA's SMR Rating (46) in the Medical Specialties industry is somewhat better than the same rating for HBIO (99) in the Biotechnology industry. This means that CDNA’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's Price Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for CDNA (92) in the Medical Specialties industry. This means that HBIO’s stock grew somewhat faster than CDNA’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CDNA (92) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than CDNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAHBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFCSX18.56N/A
N/A
American Century Focused Intl Gr I
UIVRX12.73N/A
N/A
MFS Intrinsic Value R6
OPOCX99.73N/A
N/A
Invesco Discovery A
FGIWX12.94N/A
N/A
Nuveen Global Infrastructure R6
VWYKX41.74N/A
N/A
Voya Small Cap Growth W

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with NTRA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-7.86%
NTRA - CDNA
43%
Loosely correlated
+2.14%
BLFS - CDNA
38%
Loosely correlated
-2.13%
VCYT - CDNA
38%
Loosely correlated
+15.48%
ABT - CDNA
37%
Loosely correlated
+0.86%
HBIO - CDNA
32%
Poorly correlated
+6.55%
More

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+6.55%
IRMD - HBIO
46%
Loosely correlated
-1.92%
A - HBIO
37%
Loosely correlated
+0.66%
RVTY - HBIO
36%
Loosely correlated
+0.65%
ICUI - HBIO
36%
Loosely correlated
+2.62%
ANGO - HBIO
35%
Loosely correlated
+1.55%
More